Juluca patents expiration

JULUCA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8080551 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2023

(5 months ago)

US7125879 VIIV HLTHCARE HIV inhibiting pyrimidines derivatives
Apr, 2025

(1 year, 6 months from now)

US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(4 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(6 years from now)

US10426780 VIIV HLTHCARE Antiviral therapy
Jan, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101629 VIIV HLTHCARE Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Aug, 2022

(1 year, 1 month ago)

Juluca is owned by Viiv Hlthcare.

Juluca contains Dolutegravir Sodium; Rilpivirine Hydrochloride.

Juluca has a total of 6 drug patents out of which 2 drug patents have expired.

Expired drug patents of Juluca are:

  • US8101629
  • US8080551

Juluca was authorised for market use on 21 November, 2017.

Juluca is available in tablet;oral dosage forms.

Juluca can be used as treatment of hiv infection.

The generics of Juluca are possible to be released after 24 January, 2031.


Market Authorisation Date: 21 November, 2017

Treatment: Treatment of hiv infection


How can I launch a generic of JULUCA before it's drug patent expiration?
More Information on Dosage

JULUCA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic